Australia: Parkinson’s disease, the second most common neurodegenerative disorder afterAlzheimer’s, affects over 10 million people globally, with symptoms typically emerging after age 50. Patients often rely on multiple daily tablets to manage symptoms like tremors, stiffness, and balance issues. Now, Australian scientists have developed a potential weekly injectable treatment. If proven safe and effective, this long-acting therapy could significantly improve the quality of life for those withParkinson’s. In a recent study published inDrug Delivery and Translational Research, Professor Sanjay Garg from the Centre for Pharmaceutical Innovation, University of South Australia, and his team explored the development of an in-situ forming implant system designed to provide sustained delivery oflevodopaandcarbidopa—two standard drugs used to treat Parkinson’s disease symptoms. The primary objective was to alleviate the burden of frequent oral dosing and improve medication adherence among patients. The study led to the following findings: The researchers highlighted that this in-situ forming implant system offers a simple, cost-effective, and scalable approach to long-acting drug delivery for Parkinson’s disease. By reducing the dosing frequency, the new formulation has the potential to significantly improve medication adherence and alleviate the treatment burden on elderly patients. The researchers concluded, "If further validated in clinical trials, this weekly injectable therapy could mark a significant step forward in Parkinson’s disease management, offering patients a more convenient and consistent treatment option." Nakmode, D.D., Abdella, S., Song, Y. et al. Development of an in-situ forming implant system for levodopa and carbidopa for the treatment of parkinson’s disease. Drug Deliv. and Transl. Res. (2025). https://doi.org/10.1007/s13346-025-01892-y